Musidora Biotechnology LLC
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Mar 2036
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 21, 2026The maintenance fee for Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis (US 10,295,527) comes due Nov 21, 2026. Unpaid by May 21, 2027, it lapses early.
- 1 fee due Oct 2, 2027The maintenance fee for Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment (US 11,946,927) comes due Oct 2, 2027. Unpaid by Apr 3, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 4 of 4
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,295,527 | Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis In force · USPTO record | In force | USPTO record | |
| US 11,199,534 | Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis In force · USPTO record | In force | USPTO record | |
| US 11,085,912 | Methods of Diagnosing Clostridium Difficile Infection or Recurrence in a Subject In force · High confidence | In force | High confidence | |
| US 11,946,927 | Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 4: 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.